Searing FDA Review Reveals More Clovis Credibility Slips
This article was originally published in Scrip
Executive Summary
A negative review by the FDA of Clovis Oncology Inc.'s application for its experimental lung cancer drug rociletinib not only spelled more trouble for the future approvability and marketability of the product, but also revealed more questionable behavior by the company – dealing another blow to the firm's credibility, which could be a bigger problem for the Colorado biotech in the long run.